About CellaVision
CellaVision is a world-leading provider of digital hematology microscopy solutions that automate and transform the process of performing blood differentials for laboratories of all sizes. Founded over 30 years ago and headquartered in Lund, Sweden, the company has sold more than 9,500 units across over 40 countries. CellaVision's comprehensive portfolio includes advanced digital cell morphology analyzers, software applications, reagents, and staining systems that enable laboratories to automate, standardize, and simplify morphological examination of blood and body fluid samples. The company's technology replaces manual microscopy with automated digital imaging systems that improve efficiency, connectivity, and proficiency while minimizing human error. CellaVision serves both human and veterinary hematology laboratories, offering scalable solutions adapted to customer needs regarding analysis capacity, sample preparation, data centralization, and workflow monitoring. With 250 employees globally and market support offices in 13 markets, CellaVision manufactures analyzers through outsourced production in Sweden while performing in-house stain manufacturing in Bordeaux, France. The company's solutions cover peripheral blood analysis, bone marrow aspirate examination, body fluid analysis, and advanced RBC applications, supported by proficiency software for training and competency development.
Clinical Focus
Medical conditions and clinical areas addressed by CellaVision.
Who It Serves
Milestones & Awards
Recent Milestones
Launch of Digital Cell Morphology Software 7.2 (largest software update); Launch of Bone Marrow Aspirate Application in EMEA region (2026)
Company Details
- Headquarters
- Lund, Sweden
- Employees
- 201-500
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.